2. Search Result
Search Result
Results for "

Anti-Tuberculosis agent

" in MedChemExpress (MCE) Product Catalog:

60

Inhibitors & Agonists

4

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W010589
    L-2-Aminobutyric acid

    H-Abu-OH

    		 Endogenous Metabolite Drug Intermediate Metabolic Disease
    L-2-Aminobutyric acid (H-Abu-OH) is a non-proteinogenic amino acid that exists in human tissues and body fluids. L-2-Aminobutyric acid is formed by the transamination of oxobutyric acid. L-2-Aminobutyric acid can serve as a precursor for anticonvulsant and anti-tuberculosis agents and is a key intermediate in the chemical and pharmaceutical industries.
    L-2-Aminobutyric acid
  • HY-111747
    TBAJ-587
    3 Publications Verification

    		 Bacterial Infection Cardiovascular Disease
    TBAJ-587, a potent anti-tuberculosis agent, inhibits M.tb strain H37Rv growth with MIC90s of 0.006 and <0.02 μg/mL in MABA and LORA assay, respectively. TBAJ-587 inhibits hERG channel minimally, attenuates inhibition of the cardiac potassium channel protein coded by the hERG, which is important for cardiac repolarization .
    TBAJ-587
  • HY-145286
    IMPDH2-IN-2

    		Bacterial Infection Cancer
    IMPDH2-IN-2 is a potent inhibitor of inosine 5’-monophosphate dehydrogenase (IMPDH) with a Ki,app value of 14 μM, respectively. IMPDH2-IN-2 displays moderate antibacterial activity (MIC = 6.3 and 11 μM in minimal GAST/Fe and rich 7H9/ADC/Tween media, respectively). IMPDH2-IN-2 is a potential anti-tuberculosis agent .
    IMPDH2-IN-2
  • HY-148564
    TBI-166

    		Bacterial Infection
    TBI-166, a riminophenazine analogue, is an orally active anti-tuberculosis agent with fewer adverse reactions than the lead riminophenazine compound, Clofazimine (HY-B1046) .
    TBI-166
  • HY-W028047
    JFD01307SC

    		Bacterial Infection Inflammation/Immunology
    JFD01307SC is a glutamine synthetase inhibitor and anti-tuberculosis agent. JFD01307SC acts as a mimic of L-Glutamate and thus target enzymes involved in glutamine biosynthesis .
    JFD01307SC
  • HY-146446
    PXYC1

    		Bacterial Antibiotic Infection
    PXYC1 is a ribosomal protein S1 (RpsA) antagonist with Kds of 0.81 and 0.31 μM for RpsA-CTD and RpsA-CTD Δ438A, respectively. RpsA plays an important role in the trans-translation process of Mycobacterium Tuberculosis (Mtb) .
    PXYC1
  • HY-14990
    Sudoterb

    LL 3858

    		 Bacterial Infection
    Sudoterb (LL 3858) is an orally active anti-Tuberculosis agent .
    Sudoterb
  • HY-112091
    GSK2200150A

    		Bacterial Infection
    GSK2200150A, identified by high-throughput screening (HTS) campaign, is an anti-tuberculosis (TB) agent.
    GSK2200150A
  • HY-128866A
    (Rac)-TBAJ-876

    		Bacterial Infection
    (Rac)-TBAJ-876 is a racemate of TBAJ-876. TBAJ-876 is the inhibitor of mycobacterium tuberculosis. TBAJ-876 is the analogue of the anti-tuberculosis agent Bedaquiline (HY-14881). TBAJ-876 has the potential for the research of tuberculosis .
    (Rac)-TBAJ-876
  • HY-146158
    Fudapirine

    WX-081

    		 Bacterial Potassium Channel Antibiotic Infection
    Fudapirine, an anti-tuberculosis agent, displays excellent anti-mycobacterial activity against M. tuberculosis H37Rv and low cytotoxicity. Fudapirine exhibits potent activity with MIC50s of 0.083 and 0.11 μg/mL for agent susceptible tuberculosis (DS-TB) and multidrug resistant tuberculosis (MDR-TB) strains. Fudapirine also inhibits hERG channel with the IC50 of 1.89 μM.
    Fudapirine
  • HY-178436
    Antituberculosis agent-16

    		Bacterial Infection
    Antituberculosis agent-16 is an orally active antituberculosis agent. Antituberculosis agent-16 exhibits stable antituberculosis activity with a MIC of 0.48 μg/mL against Mycobacterium tuberculosis H37Rv sensitive strain and 0.49 μg/mL against multidrug-resistant strain 14862. Antituberculosis agent-16 shows high Caco-2 permeability. Antituberculosis agent-16 can be used for the research of infection .
    Antituberculosis agent-16
  • HY-B1040
    Ftaxilide
    1 Publications Verification

    		 Bacterial Infection
    Ftaxilide is a novel antituberculosis agent.
    Ftaxilide
  • HY-W064918
    NITD-304

    		Bacterial Infection
    NITD-304 is an orally active anti-tuberculosis agent. NITD-304 exerts inhibitory and bactericidal activities gainst Mycobacterium tuberculosis and multidrug-resistant Mycobacterium tuberculosis. NITD-304 inhibits mycobacterial cell wall biosynthesis and demonstrates synergistic or additive growth inhibitory activity with select antibacterial agents. NITD-304 shows low risk of cardiotoxicity and drug-drug interactions, with no inhibition of major cytochrome P-450 enzymes or hERG channel. NITD-304 can be used for the research of tuberculosis and multidrug-resistant tuberculosis .
    NITD-304
  • HY-151514
    Antituberculosis agent-5

    		Bacterial Infection
    Antituberculosis agent-5 (compound 52) is a nitrofuranylamide derivative, inhibits M. tuberculosis UDP-Gal mutase. Antituberculosis agent-5 inhibits Glf activity with an IC50 value of 99 μM/mL and resists tuberculosis (TB) with a MIC value of 1.6 μg/mL .
    Antituberculosis agent-5
  • HY-152138
    Antituberculosis agent-8

    		Bacterial Fungal Infection
    Antituberculosis agent-8 (Compound 9i) is an antitubercular agent with an MIC of 3.53 μM (1.6 μg/mL) against M. tuberculosis H37Rv. Antituberculosis agent-8 also shows good antifungal activity against A. niger with an MIC of 62.50 μM .
    Antituberculosis agent-8
  • HY-146451
    PXYC12

    		Bacterial Antibiotic Infection
    PXYC12 is a ribosomal protein S1 (RpsA) antagonist with Kds of 2.67 and 4.67 μM for RpsA-CTD and RpsA-CTD Δ438A, respectively. RpsA plays an important role in the trans-translation process of Mycobacterium Tuberculosis (Mtb) .
    PXYC12
  • HY-142031
    4-Piperidinecarboxamide

    		Bacterial Infection
    4-Piperidinecarboxamide is a mycobacterial aspartyl-tRNA synthetase (AspS) inhibitor. 4-Piperidinecarboxamide is a promising anti-tuberculosis (TB) agent .
    4-Piperidinecarboxamide
  • HY-146057
    Antituberculosis agent-2

    		Bacterial Infection
    Antituberculosis agent-2 (Compound 8d) is an antituberculosis agent against agent-sensitive and multidrug-resistant tuberculosis. Antituberculosis agent-2 shows anti-tuberculosis activity with MIC values of 0.454, 1.757 and 1.644 μg/mL against M. tuberculosis H37Rv, 13946 and 14862, respectively. Antituberculosis agent-2 displays favorable mouse and human microsomal stability, low cytotoxicity, and acceptable oral bioavailability .
    Antituberculosis agent-2
  • HY-W738288
    Rifamdin

    		Bacterial Drug Derivative DNA/RNA Synthesis Infection
    Rifamdin is a derivative of Rifampicin (HY-B0272). Rifamdin is an anti-tuberculosis agent. Rifamdin exerts its antibacterial effect by inhibiting the synthesis of bacterial RNA .
    Rifamdin
  • HY-N11259
    Sophoradiol

    		Bacterial Infection
    Sophoradiol is a triterpenoid compound that can be extracted from Abrus Precatorius. Sophoradiol is an orally effective anti-tuberculosis agent. Sophoradiol has inhibitory activity against various strains of Mycobacterium tuberculosis. Sophoradiol has good biocompatibility. Sophoradiol can be used in the research of tuberculosis .
    Sophoradiol
  • HY-152136
    Antituberculosis agent-6

    		Bacterial Fungal Infection
    Antituberculosis agent-6 (compound 9g) is a potent antimycobacterial agent. Antituberculosis agent-6 shows significant activity against M. tuberculosis, with a MIC of 3.49 μM. Antituberculosis agent-6 also shows good antifungal activity against A. niger, with a MIC of 62.50 μM. Antituberculosis agent-6 shows high GI absorption .
    Antituberculosis agent-6
  • HY-151205
    Antituberculosis agent-3

    		Bacterial Infection Inflammation/Immunology
    Antituberculosis agent-3 (Compound 2) is an antituberculosis agent. Antituberculosis agent-3 shows anti-mycobacterial activity, and can inhibit M. tuberculosis H37Rv strain growth (MIC=12.5 μg/mL) .
    Antituberculosis agent-3
  • HY-146055
    Antituberculosis agent-1

    		Bacterial Infection
    Antituberculosis agent-1 (Compound 8a) is an antituberculosis agent with an MIC of 3.84 μg/mL against M. tuberculosis H37Rv .
    Antituberculosis agent-1
  • HY-163486
    Antituberculosis agent-10

    		Bacterial Infection
    Antituberculosis agent-10 (Compound 9) has excellent antibacterial activity against Mycobacterium tuberculosis (MIC = 0.3 μM). Antituberculosis agent-10 inhibits protein synthesis by targeting the 50S ribosomal subunit of the bacterium, thus exerting its antibacterial effect. Antituberculosis agent-10 is orally active .
    Antituberculosis agent-10
  • HY-152137
    Antituberculosis agent-7

    		Bacterial Fungal Antibiotic Infection Inflammation/Immunology
    Antituberculosis agent-7, an oxetanyl-quinoline derivative, has shown good antibacterial activity against P. mirabilis with a MIC of 31.25 μM. Antituberculosis agent-7 shows good antifungal activity against A. niger with a MIC of 62.5 μM. Antituberculosis agent-7 shows excellent antimycobacterial activity with MIC 3.41 μM for M. tuberculosis H37Rv .
    Antituberculosis agent-7
  • HY-175183
    Antituberculosis agent-15

    		Bacterial Infection
    Antituberculosis agent-15 (Compound 18c) is a selective antimycobacterial agent with MICs of 0.45 and 0.28  μM for M. tuberculosis H37Rv (ATCC 27294) and its wild-type H37Rv-LP (ATCC 25618), respectively. Antituberculosis agent-15 has potent intracellular inhibitory activities in macrophage infection models with IC50s of 0.16  μM. Antituberculosis agent-15 can be used for tuberculosis research .
    Antituberculosis agent-15
  • HY-168860
    Antituberculosis agent-13

    		Bacterial Infection Cancer
    Antituberculosis agent-13 (Compound 11) inhibits Mycobacterium tuberculosis, that inhibits Mtb wildtype and mutated strains with IC50 of 4-62.5 nM. Antituberculosis agent-13 exhibits anti-leukemia activity that inhibits MOLM-13 with IC50 of 3.8 μM .
    Antituberculosis agent-13
  • HY-W129661
    Pyrazine-2-carbothioamide

    		Bacterial Infection
    Pyrazine-2-carbothioamide is an effective antituberculosis agent with inhibitory activity against mycobacterium in vitro .
    Pyrazine-2-carbothioamide
  • HY-149064
    Antituberculosis agent-9

    		Bacterial Infection
    Antituberculosis agent-9 (Compound 5a) is an orally active antitubercular agent with an MIC of 0.5 μg/mL against H37Ra .
    Antituberculosis agent-9
  • HY-14990A
    Sudoterb hydrochloride

    LL 3858 hydrochloride

    		 Bacterial Infection
    Sudoterb (LL 3858) hydrochloride is an orally active anti-Tuberculosis agent .
    Sudoterb hydrochloride
  • HY-153009
    MMV676584

    		Bacterial Infection
    MMV676584 has anti-tuberculosis avtivity. MMV676584 is a novel agent candidate for eumycetoma .
    MMV676584
  • HY-179444
    Antituberculosis agent-17

    		Bacterial Inflammation/Immunology
    Antituberculosis agent-17 (compound 21) is a potent and selective antituberculosis agent. Antituberculosis agent-17 displays excellent anti-Tuberculosis (TB) activity against H37Rv, MDR and XDR strains of TB (MIC = 0.2-0.78 μM). Antituberculosis agent-17 exhibits selectivity for Mycobacterium tuberculosis over selected non-TB forming mycobacteria and bacteria. Antituberculosis agent-17 can be used for TB research .
    Antituberculosis agent-17
  • HY-126131
    anti-TB agent 1

    		Bacterial Infection
    anti-TB agent 1 is a potent and orally active anti-tuberculosis agent, with MICs of < 2 nM against the Mtb strains H37Rv, rRMP and rINH .
    anti-TB agent 1
  • HY-146348
    Tuberculosis inhibitor 5

    		Bacterial Infection
    Tuberculosis inhibitor 5 (Compound 11i) is a potent antimycobacterial biphenyl analogue without noticeable cytotoxicity. Tuberculosis inhibitor 5 is an anti-tuberculosis agent .
    Tuberculosis inhibitor 5
  • HY-W018677S
    Quinoxaline-d4

    		Antibiotic Infection
    Quinoxaline-d4 is the deuterium labeled Quinoxaline . Quinoxaline is a chemical compound that acts as an intermediate for anti-tuberculosis agent Pyrazinamide. Quinoxaline presents a structure that is similar to quinolone antibiotics .
    Quinoxaline-d4
  • HY-N8388
    Collinin

    		Bacterial Infection
    Collinin is a anti-tubercular agent, it can be isolated from leaves of Z. schinifolium. Collinin has an excellent anti-tuberculosis effect against multidrug-resistant (MDR), extensively drug-resistant (XDR) strains .
    Collinin
  • HY-162527
    Antibacterial agent 216

    		Bacterial Infection
    Antibacterial agent 216 (Compound 2a) is an antibacterial agent that exhibits significant bactericidal effects when combined with INH and RIF. Antibacterial agent 216 has demonstrated remarkable in vitro anti-tuberculosis activity against Mtb H37Rv and MDR clinical isolates and can be used for tuberculosis research .
    Antibacterial agent 216
  • HY-W026339
    IMB-XMA0038

    		Bacterial Infection
    IMB-XMA0038 is a MtASADH inhibitor with an IC50 value of 0.59 μg/mL. IMB-XMA0038 inhibits various agent-resistant Mycobacteria tuberculosis potently with MICs of 0.25-0.5 μg/mL. IMB-XMA0038 shows anti-tuberculosis activity .
    IMB-XMA0038
  • HY-162521
    Antibacterial agent 215

    		Bacterial Fungal Infection
    Antibacterial agent 215 (Compound 3b) is an inhibitor for carbonic anhydrase (CA), with Ki of 17.61, 5.14 and 43.74 nM, for hCA I, hCA II and AChE, respectively. Antibacterial agent 215 exhibits anti-tuberculosis, with MIC of 62.5 µg/ml against M. tuberculosis. Antibacterial agent 215 exhibits antifungal activities against Candida spp. strains ATCC 14053, ATCC 1369, and ATCC 15126, with MICs of 125 µg/ml .
    Antibacterial agent 215
  • HY-40156A
    Mycobacterium Tuberculosis-IN-5

    		Bacterial Infection
    Mycobacterium Tuberculosis-IN-5 (Compound 11) is the HCl salt form of 5-Fluoroindole (HY-40156). Mycobacterium Tuberculosis-IN-5 is an antibacterial agent, that inhibits Mycobacterium tuberculosis with a MIC of 29.1 μM. Mycobacterium Tuberculosis-IN-5 exhibits metabolic stability in rat liver microsomes. Mycobacterium Tuberculosis-IN-5 exhibits anti-tuberculosis efficacy in mice .
    Mycobacterium Tuberculosis-IN-5
  • HY-138958
    HT1171

    		Bacterial Virus Protease Infection
    HT1171 is a potent and selective inhibitor of mycobacterium tuberculosis proteasome. HT1171 shows strong anti-tuberculosis activity against Mycobacterium tuberculosis H37Rv with an MIC90 of 2 μg/mL and an MIC of 4 μg/mL. When HT1171 concentration is 100 μM, the inhibition rate of human normal hepatocytes L02 is 53.8%. HT1171 can be used in the research of antitubercular agent .
    HT1171
  • HY-W010589S2
    L-2-Aminobutyric acid-d6

    H-Abu-OH-d6

    		 Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate Metabolic Disease
    L-2-Aminobutyric acid-d6 is the deuterium labeled L-2-Aminobutyric acid. L-2-Aminobutyric acid is a non-proteinogenic amino acid that exists in human tissues and body fluids. L-2-Aminobutyric acid is formed by the transamination of oxobutyric acid. L-2-Aminobutyric acid can serve as a precursor for anticonvulsant and anti-tuberculosis agents and is a key intermediate in the chemical and pharmaceutical industries.
    L-2-Aminobutyric acid-d6
  • HY-W010589S
    L-2-Aminobutyric acid-d3

    H-Abu-OH-d3

    		 Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate Metabolic Disease
    L-2-Aminobutyric acid-d3 is the deuterium labeled L-2-Aminobutyric acid. L-2-Aminobutyric acid is a non-proteinogenic amino acid that exists in human tissues and body fluids. L-2-Aminobutyric acid is formed by the transamination of oxobutyric acid. L-2-Aminobutyric acid can serve as a precursor for anticonvulsant and anti-tuberculosis agents and is a key intermediate in the chemical and pharmaceutical industries.
    L-2-Aminobutyric acid-d3
  • HY-W010589R
    L-2-Aminobutyric acid (Standard)

    H-Abu-OH (Standard)

    		 Reference Standards Endogenous Metabolite Drug Intermediate Metabolic Disease
    L-2-Aminobutyric acid (Standard) is the analytical standard of L-2-Aminobutyric acid. This product is intended for research and analytical applications. L-2-Aminobutyric acid is a non-proteinogenic amino acid that exists in human tissues and body fluids. L-2-Aminobutyric acid is formed by the transamination of oxobutyric acid. L-2-Aminobutyric acid can serve as a precursor for anticonvulsant and anti-tuberculosis agents and is a key intermediate in the chemical and pharmaceutical industries.
    L-2-Aminobutyric acid (Standard)
  • HY-162926
    Antituberculosis agent-12

    		Bacterial Infection
    Antituberculosis agent-12 (compound 3408) is a narrow-spectrum antituberculosis prodrug phosphate that has the ability to inhibit drug-resistant tuberculosis infection .
    Antituberculosis agent-12
  • HY-151599
    Pks13-TE inhibitor 3

    		Bacterial Infection
    Pks13-TE inhibitor 3 (compound 23) is a 13-Thioesterase (Pks13-TE) inhibitor (IC50=1.55 μM). Pks13-TE inhibitor 3 shows good anti-tuberculosis activity against both agent-sensitive and drug-resistant Mtb strains (MIC=0.0625-0.25 μg/mL). Pks13-TE inhibitor 3 can be used in studies of multidrug-resistant TB and extensively drug-resistant TB .
    Pks13-TE inhibitor 3
  • HY-151598
    Pks13-TE inhibitor 2

    		Bacterial Infection
    Pks13-TE inhibitor 2 (compound 32) is a 13-Thioesterase (Pks13-TE) inhibitor (IC50=1.30 μM). Pks13-TE inhibitor 2 shows good anti-tuberculosis activity against both agent-sensitive and drug-resistant Mtb strains (MIC=0.0039-0.0078 μg/mL). Pks13-TE inhibitor 2 can be used in studies of multidrug-resistant TB and extensively drug-resistant TB .
    Pks13-TE inhibitor 2
  • HY-155067
    Antitubercular agent-38

    		Bacterial Infection
    Antitubercular agent-38 is an orally active Benzothiazinones (BTZs) derivate, with potent antituberculosis activity. Antitubercular agent-38 exhibits low cardiac toxicity, low cell cytotoxicity .
    Antitubercular agent-38
  • HY-139863
    Antibacterial agent 62

    		Bacterial Infection
    Antibacterial agent 62 is a novel redox cycling antituberculosis chemotype with potent bactericidal activity against growing and nutrient-starved phenotypically drug-resistant nongrowing bacteria.
    Antibacterial agent 62
  • HY-173355
    RCB18350

    		Bacterial Infection
    RCB18350 is an antituberculosis agent that belongs to the class of isoxazole derivatives. RCB18350 has bacteriostatic activity and inhibits the growth of Mycobacterium tuberculosis with an MIC of 1.25 μg/mL. RCB18350 is effective against multidrug-resistant Mycobacterium tuberculosis (MDR-TB) clinical isolates, slow-growing mycobacteria such as Mycobacterium bovis BCG and Mycobacterium avium .
    RCB18350

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: